Skip to main content
 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 17, 2025
Expenses
$300,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5

Issues relating to the STRONGER Patents Act and Section 101 reform

Issues related to MDUFA implementation; FDA staffing Issues relating to the medical product supply chain Issues related to medical device sterilization and the use of ethylene oxide to sterilize medical devices Issues related to HR 3723 - the Medical Device Electronic Labeling Act Issues related to PFAS and EtO Chemical regulation Issues related to the Valid Act of 2023 - H.R. 2369 Issues related to cyber security Issues related to consumer and health data privacy Issues related to regulation and reimbursement of artificial intelligence in healthcare Issues related to FDA's third party review program

Issues related to Medicare coverage reform Issues related to the coverage for FDA Breakthrough products and the H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act TCET Issues related to the New Technology Add on Payment (NTAP) Issues related to Medicare coverage for digital health technologies Issues related to coverage of telehealth services Issues related to physician fee schedule Issues related to CMS expansion of prior authorization requirements for medical procedures

Issues related to R&D tax credit

Issues related to trade and tariffs

 Bills named in this filing 3
  • H.R. 3723
    Medical Device Electronic Labeling Act
  • H.R. 2369
    VALID Act of 2023
  • H.R. 1691
    Ensuring Patient Access to Critical Breakthrough Products Act of 2024

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem